Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Madeleine Duvic, MD, Joseph D Khoury, MD, Keyur Patel, MD, Naval Daver, MD, Susan O'Brien, MD, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Elias Jabbour, Nitin Jain, MD, Stefan Faderl, MD, Deborah Thomas, MD, Arthur E. Frankel, MD, Muzaffar H. Qazilbash, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3746.

https://doi.org/10.1182/blood.V126.23.3746.3746

Published: 2015

Journal Articles

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab

Yogin B Patel, PharmD, Hagop M. Kantarjian, MD, Deborah Thomas, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, Marina Konopleva, MD PhD, Nitin Jain, MD, Rebecca Garris, Jane Autry, RN, Elias Jabbour

Blood (2015) 126 (23): 2530.

https://doi.org/10.1182/blood.V126.23.2530.2530

Published: 2015

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kantarjian Hagop, MD, Deborah Thomas, MD, Guillermo Garcia-Manero, MD, Daniela Hoehn, MD, PhD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD

Blood (2013) 122 (21): 2664.

https://doi.org/10.1182/blood.V122.21.2664.2664

Published: 2013

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Muhamed Baljevic, MD, Hagop M Kantarjian, MD, Deborah Thomas, MD, Michael Rytting, MD, Jyothsna Dasarathula, MBBS, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Farhad Ravandi, MD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Sherry Pierce, Mark Brandt, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2639.

https://doi.org/10.1182/blood.V122.21.2639.2639

Published: 2013

Journal Articles

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, M.D., Deborah Thomas, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, John T Manning, MD, L. Jeffrey Medeiros, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Aziz Nazha, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Stefan Faderl, MD

Blood (2012) 120 (21): 3554.

https://doi.org/10.1182/blood.V120.21.3554.3554

Published: 2012

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintás-Cardama, MD, Melanie Baccus, RN, Rebecca Garris, BSc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2012) 120 (21): 4308.

https://doi.org/10.1182/blood.V120.21.4308.4308

Published: 2012

Journal Articles

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Wei-gang Tong, MD, PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD, William Wierda, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3819.

https://doi.org/10.1182/blood.V114.22.3819.3819

Published: 2009

Journal Articles

Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF).

Elias Jabbour, MD, Hagop Kantarjian, MD, Sameer A Parikh, MD, Deborah Thomas, MD, Tapan Kadia, MD, Guillermo Garcia Manero, MD, Gautam Borthakur, MD, Sherry Pierce, RN, Mark Brandt, Jorge Cortes, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 2901.

https://doi.org/10.1182/blood.V114.22.2901.2901

Published: 2009

Journal Articles

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Sherry Pierce, Hagop Kantarjian

Blood (2008) 112 (11): 3954.

https://doi.org/10.1182/blood.V112.11.3954.3954

Published: 2008

Journal Articles

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Jorge Cortes, Gautam Borthakur, Sherry Pierce, Guillermo Garcia- Manero, Hagop Kantarjian

Blood (2008) 112 (11): 3966.

https://doi.org/10.1182/blood.V112.11.3966.3966

Published: 2008

Journal Articles

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MBBS, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Samuel Dara, MD, Rebecca Garris, BS, Partow Kebriaei, MD, Gautam Borthakur, MD, William Wierda, MD, PhD, Jan Burger, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2008) 112 (11): 2921.

https://doi.org/10.1182/blood.V112.11.2921.2921

Published: 2008

Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 1762.

https://doi.org/10.1182/blood.V112.11.1762.1762

Published: 2008

Journal Articles

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

Tapan M. Kadia, MD, Alessandra Ferrajoli, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Deborah Thomas, MD, William Wierda, MD, PhD, Srdan Verstovsek, MD, Willie Newsome, James Zwiebel, MD, Merrill Egorin, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2007) 110 (11): 1842.

https://doi.org/10.1182/blood.V110.11.1842.1842

Published: 2007

Journal Articles

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Animesh Pardanani, MD, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben Mesa, MD, John Redman, MD, Carl-Michael Staschen, MD, PhD, Jordan Fridman, PhD, Kris Vaddi, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 558.

https://doi.org/10.1182/blood.V110.11.558.558

Published: 2007

Journal Articles

Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.

Nitin Jain, MD, Hagop M. Kantarjian, MD, Carmen Fava, MD, Deborah Thomas, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, MD, Odeal Pate, RN, Jorge Cortes, MD

Blood (2007) 110 (11): 1043.

https://doi.org/10.1182/blood.V110.11.1043.1043

Published: 2007

Journal Articles

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Dushyant Verma, MD, FACP, Deborah Thomas, MD, Susan O’Brien, MD, Stefan Faderl, MD, Charles Koller, MD, Sherry Pierce, RN, Elihu Estey, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2007) 110 (11): 2832.

https://doi.org/10.1182/blood.V110.11.2832.2832

Published: 2007

Journal Articles

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Devri Brown, Rebecca Garris, Gautam Borthakur, MD, Jan Burger, MD, Partow Kebriaei, MD, Jeffrey Jorgensen, MD, Dan Jones, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2814.

https://doi.org/10.1182/blood.V110.11.2814.2814

Published: 2007

NARROW

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF).

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only